Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals
Click Here to Manage Email Alerts
The FDA recently cleared two over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes who are looking to improve overall health and wellness.
“CGMs are a tool I recommend to my patients to raise their overall awareness of factors that affect their glucose and are an invaluable holistic wellness solution," Fred St. Goar, MD, a cardiologist and medical director of El Camino Health Heart and Vascular Institute, said in an industry press release. “Research has shown that overall lower glucose exposure in the general population is associated with reduced long-term risk to developing cardiovascular disease, diabetes, Alzheimer's and certain cancers. Making CGMs widely available will undoubtedly have a dramatic effect on the overall health and well-being of the broader population.”
It was the top story in endocrinology last week.
In another top story, researchers found that exposure to most types of endocrine-disrupting chemicals decreased among pregnant and reproductive-aged women in recent years; however, women with a lower socioeconomic status may be exposed to higher chemical levels.
Read these and more top stories in endocrinology below:
FDA clears OTC CGMs for general public, adults with type 2 diabetes who do not use insulin
The FDA granted clearance for two new over-the-counter continuous glucose monitoring systems, one for adults with type 2 diabetes who do not use insulin and another for adults without diabetes, according to an industry press release. Read more.
EDC exposures for reproductive-aged women tied to socioeconomic status
Pregnant and reproductive-aged women have had recent declines in exposure to most endocrine-disrupting chemicals, though women with a lower socioeconomic status are exposed to higher chemical levels, according to a speaker at ENDO 2024. Read more.
Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome
Adults with Cushing’s syndrome who responded to relacorilant (Corcept Therapeutics) had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial. Read more.
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024. Watch here.
FDA approves dapagliflozin for children and adolescents with type 2 diabetes
The FDA approved the SGLT2 inhibitor Farxiga (dapagliflozin, AstraZeneca) to improve glycemic control among children and adolescents aged 10 years and older with type 2 diabetes, according to an industry press release. Read more.